InfuSystem (NYSEAMERICAN:INFU) Upgraded by StockNews.com to Strong-Buy

StockNews.com upgraded shares of InfuSystem (NYSEAMERICAN:INFU) from a buy rating to a strong-buy rating in a research report released on Tuesday morning.

InfuSystem Price Performance

NYSEAMERICAN:INFU opened at $8.11 on Tuesday. InfuSystem has a 52 week low of $7.40 and a 52 week high of $11.44. The stock has a market cap of $172.42 million, a price-to-earnings ratio of 270.42 and a beta of 1.30. The company has a current ratio of 1.95, a quick ratio of 1.54 and a debt-to-equity ratio of 0.56.

Institutional Investors Weigh In On InfuSystem

Several large investors have recently bought and sold shares of the business. Wasatch Advisors LP increased its stake in InfuSystem by 3.4% during the fourth quarter. Wasatch Advisors LP now owns 846,609 shares of the medical instruments supplier’s stock worth $8,923,000 after acquiring an additional 27,881 shares during the last quarter. Ranger Investment Management L.P. increased its position in shares of InfuSystem by 4.7% during the 4th quarter. Ranger Investment Management L.P. now owns 689,842 shares of the medical instruments supplier’s stock valued at $7,271,000 after purchasing an additional 30,835 shares during the last quarter. First Eagle Investment Management LLC raised its holdings in InfuSystem by 14.7% during the 4th quarter. First Eagle Investment Management LLC now owns 537,214 shares of the medical instruments supplier’s stock valued at $5,662,000 after buying an additional 68,814 shares during the period. Citigroup Inc. lifted its position in InfuSystem by 124.1% in the third quarter. Citigroup Inc. now owns 50,640 shares of the medical instruments supplier’s stock worth $488,000 after buying an additional 28,038 shares during the last quarter. Finally, WINTON GROUP Ltd purchased a new position in InfuSystem during the third quarter worth $101,000. Institutional investors own 71.13% of the company’s stock.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.